Pfizer Inc. (PFE) Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 28, 2026. Pfizer operates through two segments: Biopharma (the only reportable segment) and Pfizer CentreOne (PC1). The company is a large accelerated filer. As of July 29, 2026, approximately 5.7 billion shares of common stock were outstanding.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Total Revenues | $15,034 | $14,653 | $29,484 | $28,367 |
| Net Income (Loss) Attributable to Pfizer | $(248) | $2,910 | $2,440 | $5,877 |
| Diluted EPS | $(0.04) | $0.51 | $0.43 | $1.03 |
| Operating Cash Flow (YTD) | $3,450 | $1,753 | - | - |
| Long-Term Debt | $60,495 | $61,641 | - | - |
| Cash & Short-Term Investments | $11,699 | $13,596 | - | - |
Note: Q2 2026 Net Loss was driven primarily by non-cash asset impairments and legal charges, partially offset by a gain on the sale of the ViiV investment.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 3% in Q2 and 4% YTD compared to the prior year. Excluding Comirnaty and Paxlovid, operational revenue growth was 5% in Q2 and 6% YTD.
- Profitability Decline: Net income swung from a $2.9 billion profit in Q2 2025 to a $248 million loss in Q2 2026. This was primarily due to $4.3 billion in intangible asset impairments (related to sigvotatug vedotin and Oxbryta) and $842 million in legal charges.
- One-Time Gains: The company recognized a $1.87 billion net gain from the sale of its 11.7% investment in ViiV in Q2 2026.
- Cost Increases: Cost of sales rose 8% in Q2, and R&D expenses increased 13%, driven by spending on oncology and obesity candidates.
Guidance, Outlook, and Risks
- Restructuring Initiatives: Pfizer announced expanded cost-saving programs in August 2026. The "Realigning Our Cost Base Program" now targets $6.7 billion in total net savings through 2029. The "Manufacturing Optimization Program" targets $3.0 billion in savings through 2029. One-time costs for these new phases are estimated at $2.0 billion and $4.0 billion, respectively.
- Patent Expiries: Management expects an unfavorable revenue impact of approximately $1.1 billion in 2026 due to patent-based or regulatory exclusivity expiries.
- Regulatory & Legal Risks:
- Oxbryta: Pfizer voluntarily withdrew NDAs for Oxbryta in July 2026 after determining there was no viable pathway to return it to the U.S. market.
- Tariffs: Pfizer reached binding agreements with the U.S. Government regarding Section 232 tariffs on imported pharmaceuticals, securing a zero tariff rate until January 2029 in exchange for commitments to U.S. manufacturing and pricing measures.
- Litigation: Significant ongoing litigation includes patent disputes for Vyndaqel, Eliquis, and Comirnaty, as well as product liability suits regarding Zantac and Depo-Provera.
- Capital Allocation: The company maintains a dividend of $0.43 per share. No share repurchases were made in the first six months of 2026; remaining authorization is $3.3 billion.
Investor Verification Checklist
- Impairment Details: Verify the specific clinical data and regulatory feedback that led to the $4.3 billion impairment of sigvotatug vedotin and Oxbryta assets.
- Legal Accruals: Review the specific nature of the $842 million legal charge in Q2 and the status of the Depo-Provera and Zantac settlements.
- Restructuring Execution: Monitor the timeline and cash outflow for the newly announced $6.0 billion in one-time restructuring costs expected through 2029.
- COVID-19 Revenue Trajectory: Assess the sustainability of Comirnaty and Paxlovid revenues, which declined significantly (95% for Paxlovid in Q2) compared to the prior year.
- Tariff Agreement Terms: Confirm the specific pricing and manufacturing commitments made to the U.S. Government to maintain the zero-tariff status through 2029.